Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical study on the prevention and treatment of colorectal adenoma by regulating intestinal microecology: a randomized double-blind controlled trial

ABSTRACT: Interventions: experimental group 1:Yiyi Fuzi Baijiang Powder;experimental group 2:Sanwu Huangqin Decoction;placebo group 1:Yiyi Fuzi Baijiang Powder placebo agent;placebo group 2:Sanwu Huangqin Decoction placebo agent Primary outcome(s): recurrence rate Study Design: Parallel

DISEASE(S): Colorectal Adenoma

PROVIDER: 2693768 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A randomized, double-blind, placebo-controlled trial for the efficacy and safety of Ganoderma lucidum spore powder in the adjuvant therapy of postoperative patients with colorectal cancer

Project description:Interventions: Experimental group:Ganoderma lucidum spore powder;Control group:Placebo Primary outcome(s): Chemotherapy tolerance improvement Study Design: Single arm

| 2688644 | ecrin-mdr-crc

The randomized, double-blind and placebo parallel controlled multicenter clinical trial of the spleen aminopeptide oral freeze-dried powder combined with platinum chemotherapy for the treatment of advanced colorectal cancer

Project description:Interventions: Experimental group:Take the Spleen Aminopeptide Oral Lyophilized Powder;Control group :Take placebo Primary outcome(s): The quality of life improvement on the 42nd day Study Design: Randomized parallel controlled trial

| 2667670 | ecrin-mdr-crc

Ropinirole hydrochloride identified by iPSC drug discovery for amyotrophic lateral sclerosis: a single-centered, randomized, double-blind, placebo-controlled phase 1/2a trial

Project description:We assessed the safety and efficacy of ropinirole, a candidate drug for amyotrophic lateral sclerosis (ALS) identified using induced pluripotent stem cells (iPSCs) technology, by a randomized controlled trial (UMIN000034954). Twenty participants were randomly assigned to ropinirole or placebo for 24 weeks in the double-blind period, followed by a 24-week open-label active extension period. Primary outcomes were safety and tolerability. Secondary outcomes evaluated the therapeutic effects of ropinirole. Adverse events were mostly those previously reported, with similar rates in both groups. Participants in the ropinirole group had lived an additional 27.9 weeks without disease progression compared with the placebo group at 12 months. We validated and confirmed the efficacy of ropinirole in patients with ALS using the largest publicly available real-world registry database of ALS (PRO-ACT). The iPSCs-derived motor neurons from the participants showed the D2R expression and the potential involvement of the SREBP2-cholesterol synthetic pathway in the therapeutic effects.

2023-06-30 | GSE209696 | GEO

A clinical study on the Regulation of Intestinal Microenvironment in coIX Lachana Fujiang Powder for the prevention and Treatment of malignant neoplasia in advanced colorectal adenoma

Project description:Interventions: Experimental group:Yiyi Fuzi Baijiang Powder; placebo group:Yiyi Fuzi Baijiang Powder placebo Primary outcome(s): recurrence rate Study Design: Parallel

| 2697293 | ecrin-mdr-crc

A functional genomics predictive network model identifies regulators of inflammatory bowel disease: Microarray Analysis of Human Blood and Intestinal Biopsy Samples from a Phase 2b, Double-blind, Placebo-controlled Study of Ustekinumab in Crohn's Disease

Project description:Microarray Analysis of Human Whole Blood and Intestinal Biopsy Samples from a Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Crohn’s Disease

2017-07-07 | GSE100833 | GEO

Double-blinded Randomized Controlled Trial for Qu-Xie Capsule Regulating Gut Micro-biome and Body Immune System in Patients with Advanced Colorectal Cancer

Project description:Interventions: Experimental group:Quxie capsule;Control group:Placebo Primary outcome(s): OS Study Design: Parallel

| 2690311 | ecrin-mdr-crc

Clinical research for San-Wu-Huang-Qin decoction in the prevention and treatment of recurrence of colorectal adenoma

Project description:Interventions: Experimental group:Sanwu Huangqin decoction;control group:placebo Primary outcome(s): Recurrence rate of adenoma Study Design: Parallel

| 2692741 | ecrin-mdr-crc

The Relative Content and Distribution of Absorbed Volatile Organic Compounds in Rats Administered Asari Radix et Rhizoma Are Different between Powder- and Decoction-Treated Groups

Project description:Asari Radix et Rhizoma (ARR) is an important traditional Chinese medicine. Volatile organic compounds (VOCs) are the main active constituents of ARR. Research on the metabolite profile of VOCs and the difference of absorbed constituents in vivo after an administration of ARR decoction and powder will be helpful to understand the pharmacological activity and safety of ARR. In this study, headspace solid-phase microextraction gas chromatography mass spectrometry (HS-SPME-GC-MS) was applied to profile the VOCs from ARR in rats in vivo. A total of 153 VOCs were tentatively identified; 101 were original constituents of ARR (98 in the powder-treated group and 43 in the decoction-treated group) and 15 were metabolites, and their metabolic reactions were mainly oxidation and reduction, with only two cases of methylation and esterification, and 37 unclassified compounds were identified only in the ARR-treated group. Of the 153 VOCs identified, 131 were reported in rats after oral administration of ARR for the first time, containing 79 original constituents, 15 metabolites, and 37 unclassified compounds. In the powder-treated group, methyleugenol, safrole, 3,5-dimethoxytoluene (3,5-DMT), 2,3,5-trimethoxytoluene (2,3,5-TMT), and 3,4,5-trimethoxytoluene (3,4,5-TMT) were the main absorbed constituents, the relative contents of which were significantly higher compared to the decoction-treated group, especially methyleugenol, safrole, and 3,5-DMT. In the decoction-treated group, 3,4,5-TMT, 2,3,5-TMT, kakuol, and eugenol were the main constituents with a higher content and wider distribution. The results of this study provide a reference for evaluating the efficacy and safety of ARR.

2021-02-01 | MTBLS2053 | MetaboLights

Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: a Randomized Double-blind Placebo-controlled Trial

Project description:The gut microbiota has been implicated in obesity and cardiometabolic diseases, although evidence in humans is scarce. We investigated how gut microbiota manipulation by antibiotics (7-day administration of amoxicillin, vancomycin, or placebo) affects host metabolism in 57 obese, prediabetic men. Vancomycin, but not amoxicillin, decreased bacterial diversity and reduced Firmicutes involved in short-chain fatty acid and bile acid metabolism, concomitant with altered plasma and/or fecal metabolite concentrations. Adipose tissue gene expression of oxidative pathways was upregulated by antibiotics, whereas immune-related pathways were downregulated by vancomycin. Antibiotics did not affect tissue-specific insulin sensitivity, energy/substrate metabolism, postprandial hormones and metabolites, systemic inflammation, gut permeability, and adipocyte size. Importantly, energy harvest, adipocyte size, and whole-body insulin sensitivity were not altered at 8-week follow-up, despite a still considerably altered microbial composition, indicating that interference with adult microbiota by 7-day antibiotic treatment has no clinically relevant impact on metabolic health in obese humans. This randomized, placebo-controlled, double-blind study had a 3-armed parallel design. Overweight/obese participants were randomized to oral intake of amoxicillin, vancomycin or placebo for 7 consecutive days. After an overnight fast, subcutaneous adipose tissue biopsies were taken that were subjected to gene expression profiling by array.

2016-07-15 | E-GEOD-76003 | biostudies-arrayexpress

A Phase 2 Randomized, Double-blind Pilot Study of IL-17-Targeting with 2 Secukinumab in Moderate-to-Severe Atopic Dermatitis

Project description:This randomized, double-blind, phase 2 study aimed to investigate the efficacy and safety of secukinumab as compared to placebo in 41 subjects with moderate-to-severe AD over a 16-week period, with evaluations of clinical outcomes and molecular and cellular profiles in skin.

2020-09-01 | GSE137430 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data